Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CKDB-112
- Development stage
- Preclinical
- Lead developer
- CKD Bio
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CKDB-112 is an anti-ulcer drug candidate currently under development by CKD Bio (Chong Kun Dang Bio). It is categorized within the company's Active Pharmaceutical Ingredient (API) development sector, specifically targeting the treatment of peptic ulcers. As an anti-ulcer agent, it is intended to treat or prevent mucosal lesions in the stomach and duodenum. While specific pharmacological details such as its molecular target (e.g., proton pump inhibition or H2 receptor antagonism) have not been publicly disclosed, the project is part of CKD Bio's broader R&D efforts in specialized chemical and fermentation-based APIs.
Beyond the preview
Go deeper on CKDB-112.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CKDB-112.